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Reply from the Authors
The purpose of our study was to compare icodextrin-
induced peritonitis (IP) to bacterial peritonitis (BP). Be-
cause tissue damage after acute bacterial infection results
from excessive neutrophil infiltration and activation in
the infected tissue [1], we analyzed peritoneal neutrophil
phenotype. We found that despite a burst of intraperi-
toneal cytokines, aseptic peritonitis is associated with a
small inflow of activated neutrophils. We think that the
low number of neutrophils and the poor reactive oxygen
species production by peritoneal-infiltrating neutrophils
may account for the weak peritoneal damage occurring
during acute IP. In addition, the differences in the phe-
notypic expressions of transmigrated neutrophils that we
observed between IP and BP indicate that inflammatory
stimuli that activate neutrophils in both type of peritoni-
tis are clearly distinct. Indeed, positive intradermal skin
tests, high amounts of peritoneal cytokines, and predomi-
nance of peritoneal monocytes observed during IP argue
for a delayed-type hypersensitivity reaction. This is con-
sistent with the histologic examination of the peritoneal
biopsy obtained from a patient with IP described by
Goffin et al.
We agree with Dr. Tintillier that icodextrin-induced
peritonitis is not a benign event. Bacterial peritonitis also
is not a benign event. Our data just show that acute peri-
toneal injury is less severe during IP than BP. This result
does not mean that IP is a gentle disease. The peritoneal-
damaging potential of peritonitis is normally limited by
elimination of the primary event that initiates inflamma-
tory reaction. Persistence of the inflammatory insult may
lead to severe peritoneal injury. In the cases reported
by Goffin et al, icodextrin was not withdrawn despite
several episodes of cloudy dialysate. We think that the
major risk of peritoneal injury during IP is that it goes
unrecognized.
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7-84 PTH lowers bone
turnover and explains why the
1-84 PTH/7-84 PTH ratio
predicts bone turnover
To the Editor: In this journal’s October 2001 is-
sue, Monier-Faugere et al [1] demonstrated the clinical
significance of circulating large C-terminal parathyroid
hormone (PTH) fragments; PTH-(1-84)/large C-PTH
fragment ratio was superior to total PTH in predicting
bone turnover state in humans. They found predomi-
nance of PTH-(1-84) relative to large C-PTH fragment
predicts high bone turnover, whereas predominance of
large C-PTH fragment relative to PTH-(1-84) predicts
low bone turnover, regardless of total PTH levels. This
work’s significance has been obscured by erroneous in-
terpretations of a recent Endocrinology publication by
Langub et al, in which ∼18.5× the amount of human
C-PTH-(7-84) fragment was used to antagonize human
PTH-(1-84) in thyroparathyroidectomized rats [2]. In
contrast, only a slight excess of large C-PTH fragment
relative to PTH-(1-84) was associated with low bone
turnover per Monier-Faugere et al. The Monier-Faugere
et al study suggests 2-fold excesses of large C-PTH frag-
ment effectively antagonize full-length PTH. However,
because the antagonistic activities of human PTH-(7-84)
relative to human PTH-(1-84) was assessed in rats [2],
relative potencies of these peptides for the corresponding
human receptors cannot be ascertained from the Langub
et al study. Differences in key residues can dramati-
cally affect affinity of a ligand for a particular receptor.
Given cross-species receptor pharmacology differences,
the absolute or relative concentrations of the fragment
and full-length peptide in Langub et al are not relevant
from a clinical perspective. Rather, those findings sup-
port the Monier-Faugere et al study, demonstrating that
the PTH-(1-84)/PTH-(7-84) ratio is more clinically infor-
mative than standard total PTH assays.
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